Dicerna Pharmaceuticals, Inc.
(NASDAQ : DRNA)

( )
DRNA PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
BIIBBiogen, Inc.
0.73%296.001.4%$599.53m
AMGNAmgen, Inc.
0.85%235.991.3%$497.59m
GILDGilead Sciences, Inc.
-1.20%66.821.0%$365.38m
REGNRegeneron Pharmaceuticals, Inc.
0.76%375.002.6%$304.37m
VRTXVertex Pharmaceuticals, Inc.
-0.25%220.001.9%$274.45m
CLVSClovis Oncology, Inc.
-1.34%13.2514.7%$238.60m
ILMNIllumina, Inc.
0.44%321.993.5%$235.54m
ARWRArrowhead Pharmaceuticals, Inc.
-0.21%67.1811.4%$205.15m
ALXNAlexion Pharmaceuticals, Inc.
0.59%113.132.0%$203.97m
AAgilent Technologies, Inc.
1.73%84.861.6%$165.50m
EXASEXACT Sciences Corp.
0.29%85.4224.0%$161.05m
SRPTSarepta Therapeutics, Inc.
30.59%131.2014.6%$152.64m
BLUEbluebird bio, Inc.
3.38%86.8914.2%$141.37m
GBTGlobal Blood Therapeutics, Inc.
-1.99%76.896.0%$140.66m
BOLDAudentes Therapeutics, Inc.
-0.12%59.371.4%$134.85m

Company Profile

Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery and development of treatments for rare diseases, chronic liver diseases, cardiovascular disease, and viral liver infectious diseases. The firm uses its proprietary GalXC RNAi technology platform to build a pipeline in these therapeutic areas. The company was founded by Douglas M. Fambrough III, Mark A. Behlke, Roberto Guerciolini, James Craig Jenson and John J. Rossi in 2007 and is headquartered in Watertown, MA.